Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits

Fig. 4

miR-193b expression in BRCA patients is associated with aggressiveness and gene sets of signalling pathways of interest. A and B – Violin plots of miR-193b expression in two BRCA datasets. Dashed and dotted lines within violins represent the median and quartiles of the distributions. Within each dataset, the number of patients belonging to the TNBC or non-TNBC classification are written in parentheses at the x-axes. Statistical significance was calculated using two-tailed, unpaired t-test. Statistical significance is indicated above comparisons: p-values by asterisks **** ≤ 0.0001, *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05, ns = not significant. A miR-193b expression stratifying patients by receptor expression status in TCGA (left) and METABRIC (right) datasets. B miR-193b expression in two BRCA datasets stratifying patients by PAM50 classification into Basal, Her2, Luminal A (LumA), and Luminal B (LumB). C. Gene Set Enrichment Analysis of gene lists for positive and negative regulators of WNT signalling (blue box), c-Met signalling (purple box), and integrin signalling (orange box). Normalized enrichment scores (NES) and statistical significance by false discovery rates (FDR) are indicated below every signature. D Effect of miR-193b on the three signalling pathways, integrated according to their KEGG maps with downstream phenotypes. Target proteins probed in the HTS are shaded in lilac or pale yellow when they are repressors or activators of the pathways, respectively. miR-193b repressive or activating effect on the pathways is represented by a box around the proteins significantly regulated, of red or green colour, respectively. The chemical inhibitors’ activities are highlighted in blue (iCRT-14), purple (Capmatinib), and green (Erlotinib)

Back to article page